. . "Epinastin"@en . . "Epinastinum"@en . . . . "Epinastine is used for the prevention of itching associated with allergic conjunctivitis. It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response."@en . "The absolute bioavailability of epinastine is about 40%."@en . "12 hours"@en . "investigational"@en . . . "Epinastina"@en . "80012-43-7"@en . . "Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori, \"Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine.\" U.S. Patent US20090143359, issued June 04, 2009."@en . . "Epinastine has a multiaction effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H₂-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response."@en . "* 56 L/hr [patients with allergic conjunctivitis receiving one drop of ELESTAT\u00AE ophthalmic solution in each eye twice daily for seven days]"@en . . "(+-)-Epinastine"@en . . . . . " "@en . . . "# Walther G, Daniel H, Bechtel WD, Brandt K: New tetracyclic guanidine derivatives with H1-antihistaminic properties. Chemistry of epinastine. Arzneimittelforschung. 1990 Apr;40(4):440-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1972625 # Schilling JC, Adamus WS, Kuthan H: Antihistaminic activity and side effect profile of epinastine and terfenadine in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1990 Dec;28(12):493-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1982280"@en . "64%"@en . . . . . . "Epinastine is mainly excreted unchanged. The renal elimination is mainly via active tubular secretion."@en . . "Humans and other mammals"@en . . . . . . . "Epinastine"@en . . . . . . . "approved"@en . . . . . . "Epinastine"@en . . . . . . . "3-amino-9,13b-dihydro-1H-Dibenz(c,F)imidazo(1,5-a)azepine"@en . . . . . . . "For the prevention of itching associated with allergic conjunctivitis."@en . " "@en .